Modulation of Microglia Cannabinoid Receptor 2 to Treat Neuroinflammation in Parkinsonís Disease
Target Validation, 2015
Study Rationale: † † † † † † † † ††
Numerous studies have highlighted a potential role of neuroinflammation in Parkinsonís disease whereby the immune cells of the brain called microglia may produce inflammatory factors that are toxic to dopamine neurons. Cannabinoid type-2 receptors (CB2) are largely found on activated microglia and are increased in people with and models of Parkinsonís disease. This project aims to investigate the therapeutic potential of a novel CB2 modulator.
We hypothesize that modulation of CB2 will alter the inflammatory environment and mitigate inflammation-induced cell death.
To address this question, we will conduct detailed analysis to determine the extent of neuroprotection provided by a novel drug targeting cannabinoid type 2 receptors in a model of Parkinsonís disease. We will also use cell culture techniques to investigate the microglial response to understand the impact of inflammation on neurons after CB2 modulation.
Impact on Diagnosis/Treatment of Parkinsonís Disease: † † † † † ††
This project has potential to identify a disease-modifying treatment for Parkinsonís disease.
Next Steps for Development:
If successful, this study will open the door to further evaluate the safety and efficacy of this novel CB2 modulator in other pre-clinical models as a next step toward the clinic.
This project was selected for a Stern Discovery Award with support from the former Michael Stern Parkinson's Research Foundation, which merged with The Michael J. Fox Foundation in 2015.
Associate Professor of Physiology at Emory University School of Medicine
Location: Atlanta, Georgia, United States
Professor at University of Tennessee Health Science Center
Location: Memphis, Tennessee, United States